BioVersys (SIX: BIOV) has entered into an exclusive ansamycin drug discovery collaboration and license agreement with Hackensack Meridian Health (HMH), a U.S.-based private nonprofit health system, to jointly profile and develop ansamycin candidates.
According to BioVersys, its proprietary Ansamycin Chemistry platform has been developed by research teams in France and Switzerland and has already produced several advanced, highly potent, orally bioavailable, broad-spectrum anti-nontuberculous mycobacterial (anti-NTM) lead candidates.
In a statement, Dr. Marc Gitzinger, CEO of BioVersys, commented, “Early-stage partnerships with leading institutes and health centers from around the world grants us access to the best science to strengthen our Ansamycin Chemistry platform from which we aim to develop new clinical candidates. We are pleased to be working with the team of Profs. Thomas Dick and Véronique Dartois, and the world-renowned HMH. This collaboration emphasizes our determination to tackle NTM diseases, which are some of the most difficult bacterial diseases to cure. We strive to bring benefit to vulnerable populations at a higher risk of developing infections, like the 105,000 people known to be living with cystic fibrosis and the ~400 million patients with chronic obstructive pulmonary disease (COPD).”
